Cover Image
市場調查報告書

全球眼科治療藥市場預測

Global Ophthalmology Drugs Market to 2023 - Angiogenesis Inhibitors in wAMD Set to Retain High Market Share, While Expansive Pipeline for Glaucoma Leads the Research Landscape

出版商 GBI Research 商品編碼 550296
出版日期 內容資訊 英文 132 Pages
訂單完成後即時交付
價格
Back to Top
全球眼科治療藥市場預測 Global Ophthalmology Drugs Market to 2023 - Angiogenesis Inhibitors in wAMD Set to Retain High Market Share, While Expansive Pipeline for Glaucoma Leads the Research Landscape
出版日期: 2017年08月01日 內容資訊: 英文 132 Pages
簡介

全球眼科治療藥市場,預計2023年達到350億美元,2016年∼2023年以6.7%的年複合成長率成長。

本報告提供全球眼科治療藥市場相關調查分析,上市產品,開發平台,市場預測,企業分析,策略性整合等系統性資訊。

第1章 目錄

第2章 簡介

第3章 上市產品

  • 概要
  • Lucentis (ranibizumab)
  • Eylea (aflibercept)
  • Avastin (bevacizumab)
  • Restasis (cyclosporine)
  • Alphagan (brimonidine tartrate)
  • Lumigan (bimatoprost)
  • Xalatan (latanoprost)
  • 結論

第4章 開發平台形勢的評估

  • 概要
  • 開發平台開發形勢
  • 開發平台的分子標的
  • 臨床試驗

第5章 複數方案的市場預測

  • 市場規模全體
  • 學名藥的普及

第6章 企業分析與定位

  • 收益與市場佔有率分析:各企業
    • Novartis
    • Regeneron
    • Roche
    • Bayer
    • Allergan
    • Shire
    • Mallinckrodt
    • 參天製藥
    • Aerie
  • 企業形勢
  • 上市、開發中產品組合分析

第7章 策略性整合

  • 授權交易
  • 共同開發交易

第8章 附錄

圖表

目錄
Product Code: GBIHC450MR

Executive Summary:

Ophthalmology is a broad therapy area that consists of almost 100 disorders associated with the eyes and visual system, including such diseases as glaucoma, age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR) and dry eye syndrome (DES). Many of these disorders are progressive, and if left untreated can lead to severe visual impairment or even blindness.

The ophthalmology market is forecast to grow at a compound annual growth rate (CAGR) of 6.7% till 2023 - with the majority of this growth expected to occur in the final four years of the forecast period. Of the five key indications within the therapy area - glaucoma, AMD, DME, DR and DES - glaucoma and AMD have the most active product pipelines.

Despite the majority of pipeline activity being centered on these five key indications, there is also significant interest in developing products for other indications such as allergic conjunctivitis and retinitis pigmentosa. In 2017, Spark Therapeutics is expected to gain FDA approval for its orphan drug Voretigene Neparvovec, which is currently under development for retinitis pigmentosa and leber congenital amaurosis. If approved, it would not only be the first pharmacological treatment for an inherited retinal disease, but would also be the first gene therapy for any genetic disease to be approved by the FDA.

Six of the eight most commercially successful companies in the ophthalmology therapy area are among the top 20 pharma companies, including Roche, Allergan and Novartis. However, across the forecast period ophthalmology revenue growth for these companies is anticipated to be either negative or lower than the therapy area average. This will be due in part to the fact that ophthalmology products account for only 5% of these companies' late-stage pipelines.

At the same time, a number of small and specialized ophthalmology companies are expected to enter the market, including Santen and Aerie.

Scope:

  • The ophthalmology therapeutics market is forecast to reach $35 billion in 2023. What are the key market segments driving this growth?
  • The pipeline contains over 800 products. What molecule types and molecular targets are in the pipeline? What are the commercial prospects of promising late-stage products?
  • Despite specific drug classes such as angiogenesis inhibitors dominating the commercial landscape, there is a very high proportion of novel drug classes in the pipeline. Which drug classes account for the largest proportion of early-stage development, and how do clinical failure rates, clinical trial size and clinical trial duration differ by indication and molecular target?
  • Although they are dominant in the market, large biotech companies are anticipated to lose market share to specialty ophthalmology companies, which are much more active in the pipeline. Which of the leading companies will have the highest market share by 2023? Which new companies will enter the market?
  • What licensing and co-development deals have occurred within this therapy area since 2006?

Reasons to buy:

  • Understand the current clinical and commercial landscape through a comprehensive analysis of innovation in the ophthalmology therapeutics market, in the context of the overall pipeline and current market landscape. The report also includes analysis of the deals landscape, including both licensing deals and co-development deals. Key indications covered in detail include glaucoma, AMD, DME, DR and DES.
  • Understand the current treatment landscape, with profiles of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug's mechanism of action.
  • Analyze the ophthalmology therapeutics pipeline through a comprehensive review, segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at ophthalmology therapeutics clinical trials, to provide an insight into the risk associated with attempting to bring pipeline analgesics to market.
  • Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecast will provide an understanding of how epidemiology trends, new drug entries and new drug patent expirations will influence market value.
  • Identify the key pipeline products, with a particular focus on those due to be brought to market in the near future, as well as sales forecasts for these products.
  • Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from ophthalmology therapeutic products. In addition, analysis determines the primary factors that will drive market growth for the disease area's key companies.
  • Assess the licensing and co-development deal landscape for ophthalmology therapies.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Therapy Area Introduction
    • 2.1.1. Glaucoma
    • 2.1.2. Age-Related Macular Degeneration
    • 2.1.3. Diabetic Retinopathy
    • 2.1.4. Diabetic Macular Edema
    • 2.1.5. Dry Eye Syndrome
  • 2.2. Symptoms
  • 2.3. Diagnosis
  • 2.4. Etiology and Pathophysiology
    • 2.4.1. Etiology
    • 2.4.2. Pathophysiology
  • 2.5. Co-morbidities and Complications
  • 2.6. Prognosis
    • 2.6.1. Glaucoma
    • 2.6.2. Age-Related Macular Degeneration
    • 2.6.3. Diabetic Retinopathy and Diabetic Macular Edema
    • 2.6.4. Dry Eye Syndrome
  • 2.7. Epidemiology Patterns; Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates
    • 2.7.1. Glaucoma
    • 2.7.2. Age-Related Macular Degeneration
    • 2.7.3. Diabetic Macular Edema
    • 2.7.4. Diabetic Retinopathy
    • 2.7.5. Dry Eye Syndrome
  • 2.8. Treatment

3. Key Marketed Products

  • 3.1. Overview
  • 3.2. Lucentis (ranibizumab)
  • 3.3. Eylea (aflibercept)
  • 3.4. Avastin (bevacizumab)
  • 3.5. Restasis (cyclosporine)
  • 3.6. Alphagan (brimonidine tartrate)
  • 3.7. Lumigan (bimatoprost)
  • 3.8. Xalatan (latanoprost)
  • 3.9. Conclusion

4. Pipeline Landscape Assessment

  • 4.1. Overview
  • 4.2. Pipeline Development Landscape
  • 4.3. Molecular Targets in the Pipeline
  • 4.4. Clinical Trials
    • 4.4.1. Failure Rate
    • 4.4.2. Clinical Trial Duration
    • 4.4.3. Clinical Trial Size
    • 4.4.4. Aggregate Clinical Program Size
    • 4.4.5. Assessment of Key Pipeline Products
    • 4.4.6. Conclusion

5. Multi-Scenario Market Forecast to 2023

  • 5.1. Overall Market Size
  • 5.2. Generic Penetration
    • 5.2.1. Angiogenesis Inhibitors (VEGF/PlGF/PDGF Inhibitors)
    • 5.2.2. Antihistamines (Histamine H1 Receptor)
    • 5.2.3. Anti-inflammatory Agents (Glucocorticoid Receptor/IL-1 Receptor/Prostaglandin Receptor)
    • 5.2.4. IOP Modulators (Prostaglandins, Beta Blockers and the Rho Kinase Signaling Pathway)

6. Company Analysis and Positioning

  • 6.1. Revenue and Market Share Analysis by Company
    • 6.1.1. Novartis - Can the Approval of Fovista and Brolucizumab Offset Revenue Lost Following Patent Expirations?
    • 6.1.2. Regeneron - Will Regeneron be Able to Retain its Position in the Ophthalmology Market across the Forecast Period with Eylea Alone?
    • 6.1.3. Roche - To What Extent Will Pipeline Product Approvals Offset the Patent Expiries of Lucentis and Avastin?
    • 6.1.4. Bayer - Can Bayer Retain its Position in the Ophthalmology Market Given its Small Product Portfolio and Ophthalmology Pipeline?
    • 6.1.5. Allergan - How Will Declining Revenue from Restasis Affect Allergan's Overall Position within the Ophthalmology Therapy Area?
    • 6.1.6. Shire - How Will Anticipated New Approvals Perform Across the Forecast Period?
    • 6.1.7. Mallinckrodt - Will its Small Ophthalmology Portfolio and Limited Pipeline be Sufficient to Maintain the Position of Mallinckrodt in the Market?
    • 6.1.8. Santen - Will Santen Continue to Rely on Ophthalmology Therapy Area for the Majority of its Company Revenue?
    • 6.1.9. Aerie - Will Aerie be Able to Successfully Enter the Market with Two New Approvals?
  • 6.2. Company Landscape
  • 6.3. Marketed and Pipeline Portfolio Analysis

7. Strategic Consolidations

  • 7.1. Licensing Deals
    • 7.1.1. Deals by Region, Year and Value
    • 7.1.2. Deals by Stage of Development and Value
    • 7.1.3. Deals by Molecule Type, Mechanism of Action and Value
    • 7.1.4. Table for Licensing Deals Valued Above $100m
  • 7.2. Co-development Deals
    • 7.2.1. Deals by Region, Year and Value
    • 7.2.2. Deals by Stage of Development and Value
    • 7.2.3. Deals by Molecule Type, Mechanism of Action and Value
    • 7.2.4. Table for Co-development Deals Valued Above $100m

8. Appendix

  • 8.1. References
  • 8.2. Figures of All Clinical Stage Pipeline Products
  • 8.3. Abbreviations
  • 8.4. Disease List
  • 8.5. Methodology
    • 8.5.1. Coverage
    • 8.5.2. Secondary Research
    • 8.5.3. Market Size and Revenue Forecasts
    • 8.5.4. Pipeline Analysis
    • 8.5.5. Competitive Landscape
  • 8.6. Contact Us
  • 8.7. Disclaimer

List of Tables

  • Table 1: Ophthalmology Disease Therapeutics Market, Symptoms of Glaucoma, AMD, DME, DR and DES
  • Table 2: Ophthalmology Disease Therapeutics Market, Etiology of Glaucoma, AMD, DME, DR and DES
  • Table 3: Ophthalmology Disease Therapeutics Market, Complications associated with glaucoma, AMD, DR and DES
  • Table 4: Ophthalmology, Global, Epidemiology of Ophthalmologic Disorders, 2017
  • Table 5: Ophthalmology Disease Therapeutics Market, Treatment options available for glaucoma
  • Table 6: Ophthalmology Therapeutics Market, Global, Approved Indications for Lucentis, 2017
  • Table 7: Ophthalmology Therapeutics Market, Global, Approved Indications for Eylea, 2017
  • Table 8: Ophthalmology Therapeutics Market, Global, Off-label Indications for Avastin, 2016
  • Table 9: Ophthalmology Therapeutics Market, Global, Approved Indications for Restasis, 2017
  • Table 10: Ophthalmology Therapeutics Market, Global, Approved Indications for Alphagan, 2017
  • Table 11: Ophthalmology Therapeutics Market, Global, Approved Indications for Lumigan, 2017
  • Table 12: Ophthalmology Therapeutics Market, Global, Approved Indications for Xalatan, 2017
  • Table 13: Opthallmology, Global, Annual Revenue Forecast for Key Products ($bn), 2016-2023
  • Table 14: Ophthalmology Therapeutics Market, Global, Forecast Revenues by Company, 2016-2023
  • Table 15: Ophthalmology Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006-2017
  • Table 16: Ophthalmology Therapeutics Market, Global, Co-development Deals Valued Above $100m, 2006-2017

List of Figures

  • Figure 1: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Glaucoma (millions), 2016-2023
  • Figure 2: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Age-Related Macular Degeneration (millions), 2016-2023
  • Figure 3: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Diabetic Macular Edema (millions), 2016-2023
  • Figure 4: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Diabetic Retinopathy (millions), 2016-2023
  • Figure 5: Ophthalmology, Global, Epidemiology Patterns for Dry Eye Syndrome (millions), 2016-2023
  • Figure 6: Ophthalmology Therapeutics Market, Global, Annual Revenue for Lucentis ($bn), 2006-2023
  • Figure 7: Ophthalmology Therapeutics Market, Global, Annual Revenue for Eylea ($bn), 2011-2023
  • Figure 8: Ophthalmology Therapeutics Market, Global, Annual Revenue for Avastin ($bn), 2006-2023
  • Figure 9: Ophthalmology Therapeutics Market, Global, Annual Revenue for Restasis ($bn), 2006-2023
  • Figure 10: Ophthalmology Therapeutics Market, Global, Annual Revenue for Alphagan ($bn), 2006-2023
  • Figure 11: Ophthalmology Therapeutics Market, Global, Annual Revenue for Lumigan ($bn), 2006-2023
  • Figure 12: Ophthalmology Therapeutics Market, Global, Annual Revenue for Xalatan ($m), 2006-2023
  • Figure 13: Ophthalmology Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017
  • Figure 14: Ophthalmology Therapeutics Market, Global, Pipeline for Ophthalmology by Stage of Development, Molecule Type and Program Type, 2017
  • Figure 15: Ophthalmology Therapeutics Market, Global, Pipeline for Key Ophthalmology Indications by Stage of Development, 2017
  • Figure 16: Ophthalmology Therapeutics Market, Pipeline by Mechanism of Action (%), 2017
  • Figure 17: Ophthalmology Therapeutics Market, Global, Pipeline for Key Ophthalmology Indications by Mechanism of Action, 2017
  • Figure 18: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2017
  • Figure 19: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2017
  • Figure 20: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2017
  • Figure 21: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2017
  • Figure 22: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017
  • Figure 23: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2017
  • Figure 24: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2017
  • Figure 25: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2017
  • Figure 26: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2017
  • Figure 27: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2017
  • Figure 28: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2017
  • Figure 29: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2017
  • Figure 30: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development (months), 2006-2017
  • Figure 31: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2017
  • Figure 32: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2017
  • Figure 33: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Mechanism of Action (participants), 2006-2017
  • Figure 34: Ophthalmology, Global, Revenue Forecast for Lampalizumab ($m), 2018-2023
  • Figure 35: Ophthalmology, Global, Revenue Forecast for Fovista ($m), 2017-2023
  • Figure 36: Ophthalmology, Global, Revenue Forecast for Brolucizumab ($m), 2017-2023
  • Figure 37: Ophthalmology, Global, Revenue Forecast for Voretigene Neparvovec ($m), 2017-2023
  • Figure 38: Ophthalmology, Global, Revenue Forecast for Roclatan ($m), 2018-2023
  • Figure 39: Ophthalmology, Global, Revenue Forecast for Abicipar Pegol ($m), 2020-2023
  • Figure 40: Ophthalmology, Global, Market Size ($bn), 2016-2023
  • Figure 41: Ophthalmology, Global, Market Share of Key Products, 2016-2023
  • Figure 42: Ophthalmology, Global, Annual Revenue Forecast for Key Products ($m), 2016-2023
  • Figure 43: Ophthalmology, Global, Annual Revenue Forecast for Angiogenesis Inhibitors ($bn), 2016-2023
  • Figure 44: Ophthalmology, Global, Annual Revenue Forecast for Antihistamines ($m), 2016-2023
  • Figure 45: Ophthalmology, Global, Annual Revenue Forecast for Anti-inflammatories ($m), 2016-2023
  • Figure 46: Ophthalmology, Global, Annual Revenue Forecast for IOP-Lowering Drugs ($bn), 2016-2023
  • Figure 47: Ophthalmology Therapeutics Market, Global, Cluster by Growth and Market Share, 2016-2023
  • Figure 48: Ophthalmology Therapeutics Market, Global, Forecast Market Share by Company (%),2016-2023
  • Figure 49: Ophthalmology, Global, Companies by Compound Annual Growth Rate (%), 2016-2023
  • Figure 50: Ophthalmology, Global, Revenues by Product Type, 2014-2022
  • Figure 51: Ophthalmology, Global, Novartis Annual Revenue Forecast ($m), 2016-2023
  • Figure 52: Ophthalmology, Global, Regeneron Annual Revenue Forecast ($m), 2016-2023
  • Figure 53: Ophthalmology, Global, Roche Annual Revenue Forecast ($m), 2016-2023
  • Figure 54: Ophthalmology, Global, Bayer Annual Revenue Forecast ($m), 2016-2023
  • Figure 55: Ophthalmology, Global, Allergan Annual Revenue Forecast ($m), 2016-2023
  • Figure 56: Ophthalmology, Global, Shire Therapeutics Annual Revenue Forecast ($m), 2016-2023
  • Figure 57: Ophthalmology, Global, Mallinckrodt Therapeutics Annual Revenue Forecast ($m), 2016-2023
  • Figure 58: Ophthalmology, Global, Santen Therapeutics Annual Revenue Forecast ($m), 2016-2023
  • Figure 59: Ophthalmology, Global, Aerie Annual Revenue Forecast ($m), 2016-2023
  • Figure 60: Ophthalmology, Global, Companies by Type, 2017
  • Figure 61: Ophthalmology, Global, High-Activity and Late-Stage Pipeline Developers by Level of Ophthalmology Specialization, 2017
  • Figure 62: Ophthalmology, Global, Proportion of Total Company Revenue Attributed to Ophthalmology, 2016-2023
  • Figure 63: Ophthalmology, Global, Licensing Deals, 2006-2017
  • Figure 64: Ophthalmology Global, Licensing Deals by Indication and Value, 2006-2017
  • Figure 65: Ophthalmology, Global, Licensing Deals, 2006-2017
  • Figure 66: Ophthalmology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2017
  • Figure 67: Ophthalmology, Global, Co-development Deals, 2006-2017
  • Figure 68: Ophthalmology, Global, Co-development Deals, 2006-2017
  • Figure 69: Ophthalmology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2017
  • Figure 70: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 1
  • Figure 71: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 2
  • Figure 72: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 3
  • Figure 73: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 4
  • Figure 74: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 5
  • Figure 75: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 6
  • Figure 76: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 7
  • Figure 77: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 8
  • Figure 78: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 9
Back to Top